Parkinsonism & Related Disorders, 2016
hemiparkinsonism. Two weeks later rats were intraperitonially (i.p.) administered hemantane (5 mg... more hemiparkinsonism. Two weeks later rats were intraperitonially (i.p.) administered hemantane (5 mg/kg), amantadine (20 mg/kg), saline (6-OHDA and sham operated groups) for 21 days. On days 21, 28 and 35 after 6-OHDA injections the rats' behavior was evaluated in 'cylinder test' and 'footstep test'. To achieve levodopa-induced dyskinesia (LID), rats were started on daily injections of levodopa (10 mg/kg i.p.) three weeks after 6-OHDA injections. Abnormal involuntary movements (AIMs) for limb, axial, orolingual and rotatory movements were rated on a scale from 0 to 4. Treatment with hemantane (10 mg/kg i.p.) and amantadine (20 mg/kg i.p.) was initiated one week before levodopa therapy. Results: In the model of hemiparkinsonism, the antiparkinsonian effect of hemantane does not differ from amantadine (Table ). In the model of LID, hemantane showed significant antidyskinetic activity comparable to amantadine (Table ). Conclusions: Hemantane demonstrates an antiparkinsonian (5 mg/kg) and antidyskinetic (10 mg/kg) effect similar to amantadine (20 mg/kg).
Uploads
Papers by Rui Barreto